Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Characteristics of the simulation stages and treatment strategies

From: Impact on total population health and societal cost, and the implication on the actual cost-effectiveness of including tumour necrosis factor-α antagonists in management of ankylosing spondylitis: a dynamic population modelling study

 

Burn-in stage (historical simulation)

Main stage (prospective simulation)

One treatment strategy

Treatment strategy 1

Treatment strategy 2

Time horizon

1 Jan 1996–1 Jan 2014

1 Jan 2014–1 Jan 2034

Same as treatment Strategy 1

Maximal number of drugs a patient can receive

 NSAIDs

Five, randomly selected from ten possible drugs

After failure of two NSDAIs, the next two anti-TNF agents are considered; the remaining NSAIDs are reserved for those failing both anti-TNF agents

Five in an uninterrupted sequence, randomly selected from ten possible drugs

Same as in the burn-in stage

 Anti-TNF agents

Two, one subcutaneous and another intravenous, available from 1 Jan 2002 onwards

After failure of two anti-TNF agents, the remaining NSAIDs are considered

No longer available

Same as in the burn-in stage

  1. NSAIDs non-steroidal anti-inflammatory drugs, anti-TNF agent tumour necrosis factor-α antagonist
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us